GLP's effects appear agnostic to SUD diagnosis or substance
The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent in overweight and obese adults with established cardiovascular disease
Western blot Equal amounts (50 g) of RINm5F, INS-1, and MIN6 cell lysate were analyzed by Western blotting with rabbit anti-AMPK monoclonal antibody#ab32047 (Epitomics Technology, Berlingame, CA), rabbit anti-phospho-AMPK(Thr172) monoclonal antibody #2531 (Cell Signaling Technology, Beverly, MA), rabbit anti-PARP polyclonal antibody#9542S, anti-cleaved caspase-3, phospho-CREB/CREB, PDX1, phospho Akt/Akt and GAPDH (Cell Signaling Technology, Beverly, MA), respectively
It's absolutely delicious, 100 sugar-free with next to no carbs
Looks great